PPDTM CorEvitasTM Obesity (OBR) Drug Effectiveness and Safety Registry
ConditionObesity
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCorEvitas
About this trial
The design is an open-ended prospective observational (non-interventional) registry for subjects living with excess weight or obesity under the care of a qualified provider with documented experience treating patients with obesity
Eligibility criteria
This trial accepts healthy volunteersQualifiers
In the opinion of the investigator, the subject is considered a suitable candidate for treatment with a commercially available systemic obesity medication (see Enrollment Eligible Treatments). While subjects do not need to start an obesity medication at the time of registry enrollment, those prescribed a GLP-based or non-GLP-based obesity medication must be initiating the medication for the first time.
Is at least 18 years of age or older and has attained the legal age for consent to procedures involved in the research, under the applicable laws of the jurisdiction in which the research is being conducted at the time of enrollment.
Is willing and able to consent to participation in the registry.
Is willing and able to complete registry-related forms electronically via personal devices
Disqualifiers
Has Type 2 diabetes (T2D).
Is participating or planning to participate in a blinded clinical trial.
Trial population
Subjects enrolled in this registry will be treated according to routine clinical care; the assignment of subjects to any treatment will not be determined in advance by the protocol and will be clearly separated from the decision to include subjects in the registry
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Biospecimen collection
Other interventionBlood Samples will be collected from subjects. This is optional for the participating subjects
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Obesity Epidemiology and presentation
The major clinical outcome include an assessment of the epidemiology of Obesity. This will be determined using PROs and ClinROs which will be included as part of the case report forms.
Time frame
Every 6 months for 10 years Source ClinicalTrials.gov